Search Results

You are looking at 11 - 20 of 1,196 items for :

  • "characteristics" x
  • Refine by Access: All x
Clear All
Full access

Benjamin H. Kann, Henry S. Park, Skyler B. Johnson, Veronica L. Chiang, and James B. Yu

-beam RT to the brain who met the inclusion criteria. Statistical Methodology Patient-level characteristics included age, year of diagnosis, sex, malignancy type, Charlson-Deyo comorbidity score (CDS), race/ethnicity, insurance status, distance from

Full access

Amy A. Kirkham, Riggs J. Klika, Tara Ballard, Paul Downey, and Kristin L. Campbell

with a goniometer and with the sit and reach test following standardized instructions, 15 respectively. Statistics Baseline characteristics were compared between the total group that enrolled in the program and the group of participants with a

Full access

Héctor G. van den Boorn, Willemieke P.M. Dijksterhuis, Lydia G.M. van der Geest, Judith de Vos-Geelen, Marc G. Besselink, Johanna W. Wilmink, Martijn G.H. van Oijen, and Hanneke W.M. van Laarhoven

treatment of metastatic disease. Tools that can accurately predict survival while taking individual characteristics and treatments into account can be helpful for clinicians and patients when making treatment decisions. Within the past decade, the

Full access

Nicola Fossati, Daniel P. Nguyen, Quoc-Dien Trinh, Jesse Sammon, Akshay Sood, Alessandro Larcher, Giorgio Guazzoni, Francesco Montorsi, Alberto Briganti, Mani Menon, and Firas Abdollah

characteristics, 5 , 6 and none of these examined the interplay between insurance status, cancer characteristics, and treatment selection. This is of utmost importance, because tumor characteristics represent established predictors of cancer prognosis and play a

Full access

Carolina Villanueva, Jenny Chang, Scott M. Bartell, Argyrios Ziogas, Robert Bristow, and Verónica M. Vieira

-adherent. Chemotherapy must have been delivered subsequent to surgery, with the exception of stages IIIC–IV, in which it could have been received before or after surgery. 19 , 28 – 33 Several important patient characteristics were included as predictors: age at diagnosis

Full access

Linda Watson, Siwei Qi, Andrea DeIure, Eclair Photitai, Lindsi Chmielewski, and Louise Smith

(AUC) of receiver operating characteristic (ROC). Data were exported into SPSS Statistics, version 25 (IBM Corp) for analysis and statistical significance was set a priori at P <.05. Results Sample Characteristics Mean age at diagnosis was 63 years (SD

Full access

David S. Ettinger, Michael Kuettel, Jennifer Malin, Joan S. McClure, Mary Lou Smith, Andrew D. Zelenetz, and F. Marc Stewart

Much has changed in the treatment of cancer since the first NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) were rolled out for 8 different tumor types in November 1996. NCCN Guidelines now include involved algorithms often containing multiple treatment alternatives and detailed pathways of care that depend on more-specific patient characteristics and molecular tumor diagnostics. With 47 different individual NCCN panels, all members of the cancer care team are now better informed than ever to guide patients through the often complex decision-making required to improve the odds of successful outcomes. At the NCCN 20th Annual Conference, a distinguished panel assembled to take a closer look at these invaluable clinical practice guidelines, first glancing backward to how it all started and then forward to explore the key ingredients of trustworthy guidelines.

Full access

Nicholas G. Zaorsky, Ying Zhang, Vonn Walter, Leila T. Tchelebi, Vernon M. Chinchilli, and Niraj J. Gusani

diagnosed in the United States. The NCDB 7 records demographics, comorbidities, tumor characteristics, and overall survival (OS), and contains information regarding therapies delivered during the first course of treatment (ie, surgery, radiation therapy [RT

Full access

Claire de Oliveira, Joyce Cheng, Kelvin Chan, Craig C. Earle, Murray Krahn, and Nicole Mittmann

and identified patient and system characteristics associated with high system costs after cancer treatment. The most common trajectory consisted of patients who were low-cost in the year before cancer treatment and remained low-cost after completing

Full access

Yao Zhu, Yu Wei, Hao Zeng, Yonghong Li, Chi-Fai Ng, Fangjian Zhou, Caiyun He, Guangxi Sun, Yuchao Ni, Peter K.F. Chiu, Jeremy Y.C. Teoh, Beihe Wang, Jian Pan, Fangning Wan, Bo Dai, Xiaojian Qin, Guowen Lin, Hualei Gan, Junlong Wu, and Dingwei Ye

), but detailed clinical characteristics were not available for patients from the commercial laboratory. Patients from the laboratory were offered germline sequencing, according to the genetic testing recommendations in the NCCN Clinical Practice